Table 4. Analysis of P2RX7 haplotypes in controls and in women with CSCC and those with HPV-16 positive CSCC*.
| Haplotype | Controls (2N = 3238) |
CSCC (2N = 1014) |
HPV-16 positive CSCC (2N = 480) |
CSCC | HPV-16 positive CSCC | ||
|---|---|---|---|---|---|---|---|
| 2n (%) | 2n (%) | 2n (%) | P value (χ) | OR (95% CI) | P value (χ) | OR (95% CI) | |
| TAA | 1483 (45.8) | 490 (48.3) | 231 (48.1) | 0.16 (1.98) | 1.11 (0.96-1.27) | 0.34 (0.91) | 1.10 (0.91-1.33) |
| TGA | 871 (26.9) | 259 (25.5) | 129 (26.9) | 0.39 (0.73) | 0.93 (0.79-1.10) | 0.99 (0.01) | 1.00 (0.80-1.24) |
| TGC | 738 (22.8) | 225 (22.2) | 100 (20.8) | 0.69 (0.16) | 0.97 (0.82-1.14) | 0.34 (0.92) | 0.89 (0.70-1.13) |
| CGA | 113 (3.5) | 30 (3.0) | 16 (3.3) | 0.41 (0.67) | 0.84 (0.56-1.27) | 0.86 (0.03) | 0.95 (0.56-1.62) |
* Haplotype inferred using Haploview 4.2 program, based on the order of 253 T/C, 835 G/A, and 1513 A/C polymorphisms.
CSCC = cervical squamous cell carcinoma; HPV = human papillomavirus; OR = odds ratio; CI = confidence interval.
P value for 4 haplotypes between CSCC patients and controls: P = 0.50 (χ = 2.37, 3 df).
P value for 4 haplotypes between HPV-16 positive CSCC patients and controls: P = 0.75 (χ = 1.23, 3 df).